People with psoriasis will have new treatment option instead of Humira

SHARE People with psoriasis will have new treatment option instead of Humira
5thrlt1fnoek0mj6chf75a7.jpg

Tremfya is now approved by the Food and Drug Administration for people with moderate to severe plaque psoriasis. | Janssen Biotech

People with psoriasis will have a new treatment option for the itchy, sometimes painful condition, after the federal Food and Drug Administration approved a new psoriasis drug.

The FDA approved Tremfya for treatment of moderate to severe plaque psoriasis.

Johnson & Johnson said that, in one patient study, about seven in 10 patients getting Tremfya had clear or nearly clear skin after 24 weeks of treatment.

That compares with about four in 10 patients receiving rival AbbVie’s Humira, which treats several immune disorders and is the world’s top-selling drug. AbbVie is based in North Chicago.

The drug, which has the chemical name guselkumab, will cost $9,684 per dose, or about $58,100 per year, without insurance. That’s comparable to Humira, which costs about $59,200 a year.

Tremfya, which is injected every eight weeks, can cause infections and other serious side effects. Because it suppresses part of the immune system, it can increase the risk of developing tuberculosis and some types of cancer.

More than 7.5 million Americans are estimated to have psoriasis, a chronic inflammatory condition in which overproduction of skin cells causes raised red lesions called plaques, along with frequent pain, itching and burning sensations. Tremfya was able to both clear up lesions and help relieve those symptoms.

Johnson & Johnson, based in New Brunswick, New Jersey, sells other immune disorder treatment such as Remicade and Stelara for conditions including Crohn’s disease, ulcerative colitis and rheumatoid arthritis.

The Latest
It wasn’t immediately clear how the driver fell, Illinois State Police said.
Patrick Williams and Ayo Dosunmu are still very much in the plans for the Bulls moving forward, but they’re no longer in the starting lineup. So how can they continue to develop with less minutes, while the Bulls try and start winning games more consistently? That’s the wire the coaching staff will now walk.
The Americans are winless in 12 games against European opponents at the World Cup since 2002, losing six, and are 1-7 during the tournament’s knockout rounds.
Understanding the minds of ice anglers, a suburban great horned owl, the harvest from Wisconsin’s gun season and a question on hunting shed antlers are among the notes from around Chicago outdoors and beyond.